Suven Life shares up 2.5% on patent for neurodegenerative drug

Image
Press Trust of India Mumbai
Last Updated : Dec 29 2015 | 6:22 PM IST
Shares of Suven Life Sciences today rose by 2.5 per cent as its drug used in the treatment of disorders associated with neurodegenerative diseases received a patent each by Europe and Macau.
The stock gained 2.54 per cent to settle at Rs 268.60 on BSE. During the day, it rose by 5 per cent to Rs 275.20.
At NSE, shares of the company climbed 2.59 per cent to end at Rs 268.80.
In terms of volume, 2.71 lakh shares of the company changed hands at BSE and over 11 lakh shares were traded at NSE during the day.
"The company has been granted one product patent from Europe and one product patent from Macau corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases", Suven Life said in a BSE filing.
The patents are valid through 2030 and 2029.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 29 2015 | 6:22 PM IST

Next Story